Abstract
Purpose
Autonomic dysfunction is a distinctive but undervalued feature of hereditary transthyretin amyloidosis (ATTRv). It may predate the onset of polyneuropathy and cardiomyopathy, thereby providing crucial prognostic and therapeutic information. The objective of this study was to assess autonomic function by means of the standardized cardiovascular autonomic reflex tests (CRTs) in a cohort of subjects with genetically proven ATTRv from non-endemic areas who were in the symptomatic and pre-symptomatic stages.
Methods
All subjects enrolled in this cross-sectional study had genetically proven ATTRv. They underwent the head-up tilt test, Valsalva manoeuvre, deep breathing test, cold face test and handgrip test while under continuous blood pressure and heart rate monitoring. Based on the results of the nerve conduction study, the subjects were divided into two groups: those with polyneuropathy (ATTRv-wPN) and those without polyneuropathy (ATTRv-woPN). Age- and sex-matched healthy controls (HC) were used for comparison.
Results
Thirty-seven ATTRv subjects (19 with ATTRv-wPN, 18 with ATTRv-woPN) and 41 HC performed the CRTs. Of these 37 subjects with ATTRv, four (11%) presented neurogenic orthostatic hypotension the during head-up tilt test. Based on the results of the CRTs, autonomic dysfunction characterized by either sympathetic or parasympathetic impairment was detected in 37% and 63% of ATTRv-wPN subjects, respectively. Subjects with ATTRv-woPN presented a significant impairment of autonomic responses to the Valsalva manoeuvre compared to the HC (overshoot p = 0.004; Valsalva ratio p = 0.001).
Conclusion
Autonomic dysfunctions are frequent in subjects with ATTRv when investigated by means of standardized CRTs, and are also relevant in the pre-symptomatic stage. Cardiovagal functions are the primary functions affected, among others. This may be crucial in defining the proper diagnostic workout for early diagnosis and improving the likelihood of providing the patient with prompt administration of disease-modifying treatments.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Carroll A, Dyck PJ, de Carvalho M et al (2022) Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J Neurol Neurosurg Psychiatry 93:668–678. https://doi.org/10.1136/jnnp-2021-327909
Sekijima Y, Wiseman RL, Matteson J et al (2005) The biological and chemical basis for tissue-selective amyloid disease. Cell 121:73–85
Barroso FA, Coelho T, Dispenzieri A et al (2022) Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS). Amyloid 29:175-183 https://doi.org/10.1080/13506129.2022.2043270
Palma JA, Gonzalez-Duarte A, Kaufmann H (2019) Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management. Clin Auton Res 29:33–44. https://doi.org/10.1007/s10286-019-00623-x
Algalarrondo V, Antonini T, Théaudin M et al (2016) Cardiac dysautonomia predicts long-term survival in hereditary transthyretin amyloidosis after liver transplantation. JACC Cardiovasc Imaging 9:1432–1441. https://doi.org/10.1016/J.JCMG.2016.07.008
Freeman R, Wieling W, Axelrod FB et al (2011) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21:69–72. https://doi.org/10.1007/s10286-011-0119-5
Gonzalez-Duarte A (2019) Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis). Clin Auton Res 29:245–251. https://doi.org/10.1007/s10286-018-0514-2
González-Duarte A, Barroso F, Mundayat R, Shapiro B (2019) Blood pressure and orthostatic hypotension as measures of autonomic dysfunction in patients from the transthyretin amyloidosis outcomes survey (THAOS). Auton Neurosci Basic Clin 222:102590. https://doi.org/10.1016/j.autneu.2019.102590
Wiklund U, Kadkhodaee A, Andersson K et al (2018) Normal scores of deep breathing tests: beware of dysrhythmia in transthyretin amyloidosis. Amyloid 25:54–61. https://doi.org/10.1080/13506129.2018.1434140
Cheshire WP, Freeman R, Gibbons CH et al (2021) Electrodiagnostic assessment of the autonomic nervous system: a consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology. Clin Neurophysiol 132:666–682. https://doi.org/10.1016/J.CLINPH.2020.11.024
Manganelli F, Fabrizi GM, Luigetti M et al (2020) Hereditary transthyretin amyloidosis overview. Neurol Sci. https://doi.org/10.1007/s10072-020-04889-2
Ducla-Soares J, Alves MM, Carvalho M et al (1994) Correlation between clinical, electromyographic and dysautonomic evolution of familial amyloidotic polyneuropathy of the Portuguese type. Acta Neurol Scand 90:266–269. https://doi.org/10.1111/j.1600-0404.1994.tb02719.x
Dong HK, Zeldenrust SR, Low PA, Dyck PJ (2009) Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy. Muscle Nerve 40:363–370. https://doi.org/10.1002/mus.21332
Mathias CJ (2003) Autonomic diseases: clinical features and laboratory evaluation. J Neurol Neurosurg Psychiatry 74:iii31. https://doi.org/10.1136/JNNP.74.SUPPL_3.III31
Coutinho PM, da Silva AM, Lopes J et al (1980) Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Amyloid and amyloidosis. Excerpta Medica, Amsterdam, pp 88–98
Baschieri F, Calandra-Buonaura G, Doria A et al (2015) Cardiovascular autonomic testing performed with a new integrated instrumental approach is useful in differentiating MSA-P from PD at an early stage. Park Relat Disord 21:477–482. https://doi.org/10.1016/j.parkreldis.2015.02.011
Araki S, Yi S (2000) Pathology of familial amyloidotic polyneuropathy with TTR Met 30 in Kumamoto, Japan. Neuropathology 20:47–51
Ando Y, Adams D, Benson MD et al (2022) Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid 9(3):143-155. https://doi.org/10.1080/13506129.2022.2052838
Benson MD, Waddington-Cruz M, Berk JL et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379:22–31. https://doi.org/10.1056/nejmoa1716793
Adams D, Gonzalez-Duarte A, O’Riordan WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11–21. https://doi.org/10.1056/nejmoa1716153
Cruz MW (2019) Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review. Clin Auton Res 29:19–24. https://doi.org/10.1007/s10286-019-00625-9
Funding
This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.
Author information
Authors and Affiliations
Contributions
Conceptualization and design: PG, CR, PC. Formal analysis and investigation: PG, CR, IC. Data acquisition: CG, SL, FB, RR, EF, RD’A, GB. Writing—original draft preparation: PG, IC. Writing—review and editing: RC, GCB, NG, RM, PC.
Corresponding author
Ethics declarations
Conflict of interest
The authors report no relevant disclosures or conflicts of interest for this manuscript.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Guaraldi, P., Rocchi, C., Cani, I. et al. Cardiovascular reflex tests detect autonomic dysfunction in symptomatic and pre-symptomatic subjects with hereditary transthyretin amyloidosis. Clin Auton Res 33, 15–22 (2023). https://doi.org/10.1007/s10286-022-00921-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10286-022-00921-x